Decitabine
Dacogen · Hypomethylating agent
Tumor lysis in MDS/AML.
Treanda · Benda
Alkylator · approved 2008 · 10 citations · FAERS AKI reporting ROR 2.19 (95% CI 2.01–2.38, 550 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A hybrid alkylator whose biggest renal threat is the tumor it dissolves, not the kidney itself.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Direct nephrotoxicity is uncommon; the principal renal risk is acute kidney injury from tumor lysis syndrome in high-burden disease, classically during the first cycle. TLS with renal failure is documented from the first reported case onward; TMA is rare and case-level.Source: Hummel et al., Eur J Haematol 2005
Tumor lysis within hours to days of the first cycle; TMA delayed and rare.
Distilled from: “TLS within hours to days of the first cycle; TMA delayed and rare.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
First-cycle bendamustine-rituximab can precipitate severe tumor lysis syndrome with urate nephropathy and AKI in high-burden disease (case report). PMID 42004873 (opens PubMed in a new tab)
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Tap a signature to trace where it strikes the nephron.
Crystal / Obstructive Nephropathy strikes: Tubular Lumen.
Crystal / Obstructive Nephropathy
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Bifunctional alkylating agent fusing a nitrogen-mustard group with a purine-analog benzimidazole ring, producing durable DNA cross-links and double-strand breaks with relatively limited cross-resistance to other alkylators. Used for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma (often with rituximab).
Class-level context for the major non-renal toxicities of the Alkylator class.
Hematologic
Cytopenias, thrombosis, TMA
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Do not use in patients with creatinine clearance <30 mL/min. ( 8.6 )
Kidney rows of the label's dosage tables
From the BELRAPZO label (Sep 2024) · DailyMed
No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 24,082 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
4,944 of 24,082 reports
Reported with hospitalization
9,189 of 24,082 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 2,890 of the 24,082 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Bendamustine sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Dacogen · Hypomethylating agent
Tumor lysis in MDS/AML.
Mustargen · Alkylating agent (nitrogen mustard)
Tumor lysis in bulky lymphoma is the main renal hazard; modern topical gel has no detectable systemic absorption.
Fludara · Purine analog
Tumor lysis; accumulates in renal impairment.
Cosmegen · Antitumor antibiotic
Renal risk indirect via tumor lysis in chemosensitive pediatric tumors; hepatic veno-occlusive disease is the signature organ toxicity.
Cytosar · Nucleoside analog
Tumor lysis in leukemia; high-dose toxicity.
Etopophos · Topoisomerase II inhibitor
Tumor lysis; renally cleared.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Bendamustine’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Bendamustine; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 51 clinical records among all 60 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.